Latest Breaking News On - Director garen - Page 1 : comparemela.com

Aigen Investment Management LP Takes Position in Collegium Pharmaceutical, Inc (NASDAQ:COLL)

Aigen Investment Management LP Takes Position in Collegium Pharmaceutical, Inc (NASDAQ:COLL)
wkrb13.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wkrb13.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesGareng bohlinPiper sandlerPacer advisors incQube research technologies ltdNeedham companyYork state common retirement fundHermes incSecurities exchange commissionExchange commissionCollegium pharmaceutical incAigen investment managementCollegium pharmaceuticalFree reportTechnologies ltd

Aigen Investment Management LP Takes $338,000 Position in Collegium Pharmaceutical, Inc (NASDAQ:COLL)

Aigen Investment Management LP Takes $338,000 Position in Collegium Pharmaceutical, Inc (NASDAQ:COLL)
dailypolitical.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dailypolitical.com Daily Mail and Mail on Sunday newspapers.

Piper sandlerGareng bohlinCollegium pharmaceutical company profileCollegium pharmaceutical incPacer advisors incJohnson investment counsel incSummerhaven investment managementNeedham companyAigen investment managementCollegium pharmaceuticalFree reportFinancial marketsHaven investment managementInvestment counselGet free reportDirector garen

Karyopharm Therapeutics Inc (NASDAQ:KPTI) Given Consensus Rating of Moderate Buy by Brokerages

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has been assigned an average rating of “Moderate Buy” from the six ratings firms that are covering the firm, MarketBeat reports. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1 year price […]

Piper sandlerGareng bohlinVictory capital management incBleakley financial groupPrelude capital managementKaryopharm therapeutics company profileKaryopharm therapeutics incSelective inhibitor of nuclear exportAdvisor group holdings incRoyal bankMorgan stanleySimplicity solutionsKaryopharm therapeuticsGet free reportDirector garenFinancial group

Brokerages Set Karyopharm Therapeutics Inc (NASDAQ:KPTI) Target Price at $6 67

Karyopharm Therapeutics Inc. (NASDAQ:KPTI – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the stock, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1 year price target among […]

Nova scotiaPiper sandlerGareng bohlinRoyal bankKaryopharm therapeutics incMorgan stanleyKaryopharm therapeutics company profileBlackrock incSecurities exchange commissionMarshall waceSelective inhibitor of nuclear exportKaryopharm therapeuticsGet free reportDirector garenExchange commissionStreet corp

Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $3 00 at Royal Bank of Canada

Karyopharm Therapeutics (NASDAQ:KPTI – Free Report) had its price target cut by Royal Bank of Canada from $4.00 to $3.00 in a report published on Friday morning, Benzinga reports. They currently have an outperform rating on the stock. Several other equities analysts have also commented on the company. Wedbush reiterated a neutral rating and issued […]

United statesBanque cantonale vaudoiseGareng bohlinPiper sandlerKaryopharm therapeutics incRoyal bankFund management coMorgan stanleyKennedy investment groupSelective inhibitor of nuclear exportSecurities exchange commissionKaryopharm therapeuticsFree reportGet free reportDirector garenExchange commission